Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  De Mesquita, Fernanda Cristina ^a,c   Guixé Muntet, Sergi ^a,b   Fernández Iglesias, Anabel ^a   Maeso DIáz, Raquel ^a   Vila, Sergi ^a   Hide, DIana ^a   Ortega Ribera, Martí ^a   Rosa, José Luís ^b   Garciá Pagán, Juan Carlos ^a,b   Bosch, Jaime ^a,b   De Oliveira, Jarbas Rodrigues ^c   Gracia Sancho, Jordi ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

INCRETIN; LIRAGLUTIDE;

ANIMAL; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECT; HEPATIC STELLATE CELL; HUMAN; LIVER; LIVER CIRRHOSIS; MALE; METABOLISM; MICROVASCULATURE; PATHOPHYSIOLOGY; VASCULARIZATION; WISTAR RAT;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HEPATIC STELLATE CELLS; HUMANS; INCRETINS; LIRAGLUTIDE; LIVER; LIVER CIRRHOSIS; MALE; MICROVESSELS; RATS, WISTAR;

EID: 85020750694     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-02866-y     Document Type: Article

References (48)

1. Nauck, M. A. Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, clinical implications. Am. J. Med. 124, S3-18 (2011).
2. Kazafeos, K. Incretin effect: GLP-1, GIP, DPP4. Diabetes Res. Clin. Pract. 93(Suppl 1), S32-6 (2011).
3. Drucker, D. J. The biology of incretin hormones. Cell Death Differ. 3, 153-165 (2006).
4. Gupta, N. A., et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51, 1584-1592 (2010).
5. Pyke, C., et al. GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody. Endocrinology 155, 1280-1290 (2014).
6. Wang, X.-C., Gusdon, A. M., Liu, H., Qu, S. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J. Gastroenterol. 20, 14821-14830 (2014).
7. Armstrong, M. J., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, doubleblind, randomised, placebo-controlled phase 2 study. Lancet (London, England) 387, 679-90 (2016).
8. McClean, P. L., Jalewa, J., Hölscher, C. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice. Behav. Brain Res. 293, 96-106 (2015).
9. Shiraki, A., et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 221, 375-82 (2012).
10. Fernández-Iglesias, A., Gracia-Sancho, J. How to face chronic liver disease: The sinusoidal perspective. Front. Med. 4, 7 (2017).
11. Marrone, G., et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J. Hepatol. 58, 98-103 (2013).
12. Pinzani, M., Gentilini, P. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin. Liver Dis. 19, 397-410 (1999).
13. Török, N. J. Recent advances in the pathogenesis and diagnosis of liver fibrosis. J. Gastroenterol. 43, 315-21 (2008).
14. Soon, R. K., Yee, H. F. Stellate Cell Contraction: Role, Regulation, Potential Therapeutic Target. Clin. Liver Dis. 12, 791-803 (2008).
15. Reynaert, H. Hepatic stellate cells: Role in microcirculation and pathophysiology of portal hypertension. Gut 50, 571-581 (2002).
16. Marrone, G., Shah, V. H., Gracia-Sancho, J. Sinusoidal communication in liver fibrosis and regeneration. J. Hepatol. 65, 608-17 (2016).
17. Kisseleva, T., et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc. Natl. Acad. Sci. USA 109, 9448-9453 (2012).
18. Cerini, F., et al. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J. Hepatol. 64, 834-42 (2016).
19. Gao, H., et al. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease. Biol. Pharm. Bull 694, 694-702 (2015).
20. Gaspari, T., et al. Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis. Diabetes Vasc. Dis. Res. 13, 56-68 (2016).
21. Armstrong, M. J., et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J. Hepatol. 64, 399-408 (2016).
22. Steven, S., et al. Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia. Basic Res. Cardiol. 110, 6 (2015).
23. Schuppan, D., Kim, Y. O. Evolving therapies for liver fibrosis. J. Clin. Invest. 123, 1887-1901 (2013).
24. Weiskirchen, R., Tacke, F. Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology. Hepatobiliary Surg Nutr 3, 344-363 (2014).
25. Trautwein, C., Friedman, S. L., Schuppan, D., Pinzani, M. Hepatic fibrosis: Concept to treatment. J. Hepatol. 62, S15-S24 (2015).
26. Marrone, G., et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: Behind the molecular mechanisms of statins. Gut 64, 1434-43 (2015).
27. Klein, S., et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab. Investig. 92, 1440-1450 (2012).
28. Wright, M. C., et al. Gliotoxin Stimulates the Apoptosis of Human and Rat Hepatic Stellate Cells and Enhances the Resolution of Liver Fibrosis in Rats. Gastroenterology 121, 685-698 (2001).
29. Olinga, P., Schuppan, D. Precision-cut liver slices: A tool to model the liver ex vivo. J. Hepatol. 58, 1252-1253 (2013).
30. Xie, G., et al. Role of Differentiation of Liver Sinusoidal Endothelial Cells in Progression and Regression of Hepatic Fibrosis in Rats. Gastroenterology 142, 918-927 (2012).
31. Laviola, L., et al. Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway. Endocrinology 153, 5770-81 (2012).
32. Wang, L., et al. GLP-1 analog liraglutide enhances proinsulin processing in pancreatic-cells via a PKA-dependent pathway. Endocrinology 155, 3817-28 (2014).
33. Abraldes, J. G., et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J. Hepatol. 46, 1040-6 (2007).
34. Trebicka, J., et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46, 242-253 (2007).
35. La Mura, V., et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology 57, 1172-1181 (2013).
36. Luedde, T., Schwabe, R. F. NF-B in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 8, 108-118 (2011).
37. Gaspari, T., et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/-mouse model. Diabetes Vasc. Dis. Res. 8, 117-24 (2011).
38. Pritchett, J., et al. Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans. Hepatology 56, 1108-1116 (2012).
39. Martin, K., et al. PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis. Nat. Commun. 7, 12502 (2016).
40. Gracia-Sancho, J., et al. Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. Gut 60, 517-24 (2011).
41. Cantini, G., et al. Effect of liraglutide on proliferation and differentiation of human adipose stem cells. Mol. Cell. Endocrinol. 402, 43-50 (2015).
42. Perri, R. E., et al. Defects in cGMP-PKG pathway contribute to impaired NO-dependent responses in hepatic stellate cells upon activation. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G535-42 (2006).
43. Lu, N., et al. Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PLoS One 10, e0132744 (2015).
44. Hoang, V., Bi, J., Mohankumar, S. M., Vyas, A. K. Liraglutide Improves Hypertension and Metabolic Perturbation in a Rat Model of Polycystic Ovarian Syndrome. PLoS One 10, e0126119 (2015).
45. Hide, D., et al. Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: Underlying mechanisms and pharmacological therapy. Sci. Rep. 6, 22107 (2016).
46. Gracia-Sancho, J., et al. Evidence Against a Role for NADPH Oxidase Modulating Hepatic Vascular Tone in Cirrhosis. Gastroenterology 133, 959-966 (2007).
47. Hilmer, S. N., et al. Age-related changes in the hepatic sinusoidal endothelium impede lipoprotein transfer in the rat. Hepatology 42, 1349-1354 (2005).
48. Hide, D., et al. A novel form of the human manganese superoxide dismutase protects rat and human livers undergoing ischaemia and reperfusion injury. Clin. Sci. (Lond). 127, 527-37 (2014).